LPL Financial LLC Raises Stake in Globus Medical, Inc. (NYSE:GMED)

LPL Financial LLC lifted its position in Globus Medical, Inc. ( NYSE:GMED – Free Report ) by 7.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).

The institutional investor owned 126,548 shares of the medical device company’s stock after purchasing an additional 8,987 shares during the period. LPL Financial LLC owned about 0.09% of Globus Medical worth $10,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).



A number of other hedge funds and other institutional investors have also recently modified their holdings of GMED. Oak Thistle LLC bought a new position in Globus Medical in the 4th quarter worth $376,000. bLong Financial LLC bought a new position in shares of Globus Medical in the fourth quarter worth about $397,000.

Kathmere Capital Management LLC purchased a new stake in shares of Globus Medical during the fourth quarter worth about $23,091,000. State Street Corp grew its position in shares of Globus Medical by 2.3% during the third quarter.

State Street Corp now owns 3,570,726 shares of the medical device company’s stock worth $255,450,000 after purchasing an additional 81,371 shares in the last quarter. Finally, HB Wealth Management LLC bought a new stake in Globus Medical during the 4th quarter valued at approximately $301,000. 95.

16% of the stock is owned by hedge funds and other institutional investors. Analyst Upgrades and Downgrades GMED has been the subject of a number of research analyst reports. Truist Financial cut their price objective on shares of Globus Medical from $90.

00 to $82.00 and set a “hold” rating for the company in a report on Tuesday, March 18th. Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $80.

00 to $97.00 in a research report on Thursday, January 9th. Roth Mkm lifted their price target on shares of Globus Medical from $100.

00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 17th. Canaccord Genuity Group boosted their price target on shares of Globus Medical from $92.

00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Finally, StockNews.

com lowered Globus Medical from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $97.

09. Insider Buying and Selling In related news, CFO Keith W. Pfeil sold 14,167 shares of the stock in a transaction dated Friday, January 10th.

The shares were sold at an average price of $88.29, for a total value of $1,250,804.43.

The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website . 18.54% of the stock is owned by corporate insiders.

Globus Medical Trading Down 4.5 % Shares of NYSE GMED opened at $72.07 on Friday.

Globus Medical, Inc. has a 12-month low of $49.33 and a 12-month high of $94.

93. The firm’s 50-day moving average price is $80.64 and its 200-day moving average price is $79.

96. The stock has a market capitalization of $9.91 billion, a price-to-earnings ratio of 96.

09, a P/E/G ratio of 1.61 and a beta of 1.19.

Globus Medical ( NYSE:GMED – Get Free Report ) last posted its quarterly earnings data on Thursday, February 20th. The medical device company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.

74 by $0.10. The business had revenue of $657.

29 million during the quarter, compared to analyst estimates of $646.19 million. Globus Medical had a return on equity of 10.

83% and a net margin of 4.09%. On average, equities analysts predict that Globus Medical, Inc.

will post 3.44 EPS for the current fiscal year. Globus Medical Profile ( Free Report ) Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.

The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. Featured Stories Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc.

( NYSE:GMED – Free Report ). Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter .

.